What follows is a note from Kimberly Blackwell, MD, Head of Early-Phase Development & Immuno-Oncology at Eli Lilly & Co., endorsing attendance/participation in the upcoming Precision Medicine World Conference 2019 (PMWC 2019), January 20-23 in Silicon Valley, California (venue: Santa Clara Convention Center (https://www.pmwcintl.com/2019sv/). Dr. Blackwell is the Immunotherapy Track Chair for PMWC 2019. Prior to joining Eli Lilly, Dr. Blackwell was a Professor of Medicine and Assistant Professor of Radiation Oncology at Duke University Medical Center, and she was also Co-Director of the Duke Women’s Cancer Program and Associate Director for Strategic Relations for the Duke Cancer Institute.Following is the message from Dr.Blackwell: “The Nobel Prize in Medicine was awarded on October 1, 2018 to Dr. James Allison (MD Anderson) and Dr. Tasuku Honjo (Kyoto University) for their work on unleashing the body’s immune system to attack cancer, a breakthrough that has led to an entirely new class of drugs and brought lasting remissions to many patients who had run out of options. Given these recent high-impact developments and success stories, PMWC 2019 Silicon Valley has dedicated an entire track of its program to Immunotherapy, with ten individual sessions and a fully dedicated technology showcase of companies developing products in the field. I am pleased to announce that Dr. Carl June will join me in a Fireside Chat at the opening of the Track. Dr. June was the driving force behind the first FDA-approved gene therapy – Kymriah, a chimeric antigen receptor (CAR) T cell therapy for B-cell acute lymphoblastic leukemia. See Dr. June's interview (https://www.pmwcintl.com/carl-june-2019sv-qa/).
Login Or Register To Read Full Story